AstraZeneca's Enhertu Application Accepted by FDA With Priority Review
Bernstein Initiates DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Announces Target Price $45.02
UBS Initiates DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Announces Target Price $43.35
AstraZeneca Antibody Drug Candidate Fails to Meet Overall Survival Goal in Breast Cancer
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca, Roche Cut at Deutsche After Trial Readouts for Key Drugs
AstraZeneca Reports Disappointing Phase 3 Data for Lung Cancer ADC
Merck, Daiichi Post Mid-stage Data for Novel Lung Cancer Drug
Jefferies Maintains DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Raises Target Price to $53.04
Citi Initiates DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Announces Target Price $48.4
Jefferies Maintains DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Cuts Target Price to $45.63
J.P. Morgan Maintains DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Raises Target Price to $47.41
Merck, Daiichi Sankyo Expand Cancer Drug Deal
Daiichi Sankyo Non-GAAP EPS of Yen 44.57, Revenue of Yen 436.19B
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
DAIICHI SANKYO COMPANY LIMITED To Go Ex-Dividend On September 27th, 2024 With 0.264 USD Dividend Per Share
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Merck, Daiichi Lung Cancer Therapy Rejected in U.S.
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
No Data
No Data